Experience of enzyme replacement therapy for attenuated mucopolysaccharidosis I in Marathawada, India-a case report is a research paper published in International Journal of Contemporary Pediatrics (2022). On theSindex it has a DataRank of 0.104. It has been cited 1 time.
Mucopolysaccharidosis (MPS) type I is an autosomal recessive lysosomal storage disease caused by deficiency on the enzyme α-L-iduronidase. The spectrum of severity ranges from most severe Hurler syndrome, Hurler-Scheie syndrome to mildest form as Scheie syndrome. Enzyme replacement therapy (ERT) with recombinant α-L-iduronidase (laronidase) has shown to significantly improve the quality of life in children. Here we want to describe clinical characteristics, enzyme activity and genetic finding in the first patient with MPS type I who received aldurazyme replacement therapy in Marathwada, India.
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 100% comes from its base citations and 0% from the citation network.
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.